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ABSTRACT
The mosquito-borne chikungunya virus (CHIKV) causes an acute febrile illness with rash, joint 
and muscle pain.A realtime RT-PCR assay for CHIKV detecting non-structural protein (nsP2; 
CHIKV nsP2-RT-qPCR) was set up. All the serodiagnosed CHIKV cases detected during 2009- 
2019 in Finland were screened with the assay, followed by isolations attempts and sequen-
cing using Sanger and next generation sequencing (NGS). To validate the assay external and 
in-house quality control samples were used and all were correctly identified. Specificity of the 
assay was 100%. Assay was sensitive to detect CHIKV RNA in dilution of 10-8.During years 
2009-2019 34 patients were diagnosed for acute CHIKV infection. Twelve out of 34 cases were 
positive by CHIKV nsP2-RT-qPCR.Two CHIKV isolations succeeded from two individuals 
infected originally in Thailand, 2019. From 12 CHIKV nsP2-RT-qPCR positive samples, five 
(42%) CHIKVs were successfully sequenced. In this study, CHIKVs from year 2019 clustered 
with CHIKV ECSA-lineage forming sub-cluster with strains from ones detected in Bangladesh 
2017, and the ones from Jamaica (2014) within Asian lineage showing highest similarity to 
strains detected in Caribbean outbreak 2013-15.  Majority of the CHIKV infections detected in 
Finland originates from Asia and virus lineages reflect the global circulation of the pathogen.
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Introduction
Diagnosis of febrile illnesses in travelers and people 
living in areas endemic for mosquito-borne diseases 
is a global challenge. There is a highly diverse group 
of etiological agents and diseases to consider, such as 
malaria, dengue, and enteric fevers [1]. Several of the 
mosquito-borne microbes are clinically important 
viruses, such as dengue (DENV), Zika (ZIKV), West 
Nile (WNV), and chikungunya viruses (CHIKV). 
Since tropically circulating diseases may cause life- 
threatening complications, the correct identification 
of the causative pathogen is of importance.
Globally one of the most significant mosquito- 
borne viruses is the CHIKV which belongs to the 
genus Alphavirus and causes millions of infections 
annually. CHIKV circulates in the tropical and sub-
tropical regions of Africa, Asia, and the Americas and 
its main vector species are the Aedes albopictus and 
A. aegypti mosquitoes [2]. At the moment, three 
major genetic lineages are found: West African, 
East/Central/South African (ECSA) which includes 
the Indian Ocean lineage (IOL) that emerged in 
2004, and the Asian lineage [3]. Large outbreaks 
have occurred in Asia, for example, in Thailand dur-
ing the years 2008–2009, 2013, and 2018–2019, but 
also in the Americas during 2013–15, and more 
recently, in Brazil in 2017–18 [4–12]. An acute 
CHIKV infection has a mean incubation time of 
three days and the clinical symptoms include fever, 
rash, severe joint and muscle pain, and edema in the 
joints [13]. Infection is confirmed by either serology 
or molecular methods, but in endemic regions, the 
debilitating arthralgia can also be used for a fairly 
reliable clinical diagnosis [13].
In Finland, CHIKV infections occur only in trave-
lers, reflecting the epidemiological situation in the 
endemic tropical areas. The continental subarctic cli-
mate of Finland is not suitable for the vector species 
of CHIKV [14], and consequently, there are no auto-
chthonous cases of CHIKV in Finland, unlike the 
Mediterranean more precisely Italy and France 
[15–17].
HUSLAB (HUS Diagnostic center, Helsinki, 
Finland) performs the laboratory diagnostics of 
CHIKV infections in Finland. Thirty-four CHIKV 
infections have been serodiagnosed in Finnish trave-
lers during the years 2009–2019. All of the collected 
samples were examined using CHIKV IgM ELISA 
(Euroimmun) and CHIKV nsp2-RT-qPCR followed 
by virus isolation, sequencing, and molecular epide-
miology analysis. In addition, data from the valida-
tion of a real-time reverse-transcription PCR assay 
detecting CHIKV the non-structural protein (CHIKV 
nsP2-RT-qPCR) are provided.
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Materials and methods
We screened retrospectively all the samples sent to 
HUSLAB (Helsinki, Finland) and serodiagnosed for 
acute CHIKV infection using the CHIKV nsP2-RT- 
qPCR followed by Sanger sequencing and next- 
generation sequencing (NGS) for a whole-genome 
sequencing approach. Virus isolation was attempted 
from all CHIKV nsP2-RT-qPCR positive samples.
Virus strains and samples for validation
In order to test the specificity of the CHIKV nsP2-RT 
-qPCR, a panel of 15 CHIKV antibody-negative 
human serum samples from Finnish individuals [ori-
ginally tested negative using CHIKV hemagglutina-
tion inhibition tests and immunofluorescence assays, 
HUSLAB] was used. In addition, we tested RNA 
extracted from cell culture isolations of DENV 1–4 
(Robert Koch Institute (RKI), Germany, and 
Zeptometrix Corporation, Buffalo, New York, USA), 
ZIKV (strain MR766, Zeptometrix), yellow fever 
virus (YFV, strains 17D and Asibi, RKI), and WNV 
(strain Eg101, in-house).
For validation and quality control purposes, we 
also tested CHIKV Caribbean (European Virus 
Archive) and Ross (in-house) strains as well as 12 
external quality assessment (EQA) samples distribu-
ted by the European Network for Diagnostics of 
Imported Viral Diseases (EVD-Labnet). The EQA 
samples consisted of CHIKV strains H20235 Saint 
Martin/2013 (Asian genotype), 236 origin Seychelles 
and 3162 origin India (both of the East-Central-South 
-Africa genotype) as well as O’nyong-nyong virus 
(ONNV) strain Ahero, Sindbis virus (SINV) strain 
Edgar 339, and DENV-2 strain VR-345 (EQA). The 
sample set is described thoroughly by [18].
Acute CHIKV disease samples
Altogether, 34 patients were diagnosed with acute 
CHIKV disease from 2009 until the end of 
December 2019 in Finland (Table 1). The annual 
variation of acute CHIKV cases in Finland is pre-
sented in Figure 1. The primary diagnosis has been 
made using serology, i.e. rise in IgG using IFA or 
hemagglutination inhibition titers (detects total anti-
bodies) and positive IgM test, either using immuno-
fluorescence and/or ELISA (Euroimmun) (Table 1). 
All of the patients were tested to be negative for acute 
dengue fever (HUSLAB). All patient samples were 
handled anonymously and according to research per-
mits (of projects TYH2016258, TYH2017257, and 
TYH2019263) of Helsinki University Hospital.
Extraction methods
Total nucleic acids were extracted from the serum 
and EDTA-blood samples using MagNA Pure LC 
instrument and Total Nucleic acid kit (Roche, 
Espoo, Finland). Total nucleic acid templates were 
used for nsP2-RT-qPCR and nested RT-PCR, both 
described below. For the processing of the nsP2-RT- 
qPCR reaction mixtures and total nucleic acid tem-
plates, QIAgility (Qiagen, Hilden, Germany) auto-
mated system was also used.
CHIKV RT-PCRs
We set up an in-house CHIKV nsP2-RT-qPCR based 
on previously published PCR primers (Centers for 
Disease Control and Prevention (CDC)) [19] com-
prising a 101 bp long PCR product. Two detection 
probes were designed in this study, and different 
primers and probes are presented in more detail in 
Table 2.
Real-time RT-PCR was performed using the 
SuperScript III Platinum One-Step qRT-PCR Kit 
(Invitrogen, Carlsbad, CA, USA) with 320 nM of 
the CHIKV-F primer, 240 nM of both CHIKV-R1 
and CHIKV-R2 primers and 160 nM of each probe. 
Five µl of the extracted eluate was subjected to 25 µl 
PCR-reaction with cycling conditions of 1 cycle of 50° 
C for 30 min, 1 cycle of 95°C for 2 min, followed by 
45 cycles of 95°C for 15 sec and 60°C for 50 sec.
For Sanger sequencing, nested RT-PCR primers 
described by [20] were used. Nested RT-PCR was 
carried out using a final concentration of 40 pmol 
of each primer and Superscript® III Platinum® One- 
step RT-PCR System (Invitrogen) with the final tem-
plate amount of 5 µl. The positive PCR products were 
purified using AMPure XP beads (Beckman-Coulter, 
CA, USA) and sequenced using Sanger method 
(Helsinki University sequencing services, Helsinki, 
Finland).
Virus isolation protocol
The CHIKV nsP2-RT-qPCR positive patient sam-
ples (serum/EDTA-blood) were inoculated to Vero 
cells in 2% FBS MEM with penicillin-streptomycin- 
nystatin. Seven days after the infection, RNA was 
extracted from the cultured cells using Viral RNA 
mini kit (Qiagen) and tested using CHIKV nsP2-RT 
-qPCR.
One sample (indicated in Table 1; from year 2010) 
was not used for the virus isolation attempt since the 
CHIKV detected in this sample (taken in 2010) has 
been previously described by [21].
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Next-generation sequencing, NGS
For NGS, the original serum samples were filtered 
through 0.4 µm columns (Millipore, Burlington, 
Massachusetts, US) and treated with a mixture of 
micrococcal nuclease (New England BioLabs 
Ipswich, Massachusetts, US) and benzonase 
(Millipore) for 1 hour at 37°C, followed by RNA 
extraction using Trizol reagent (Thermo Fisher 
Scientific, Massachusetts, USA). Ribosomal RNA 
was removed using a NEBNext rRNA Depletion Kit 
(New England BioLabs) according to the manufac-
turer’s protocol. The sequencing library was prepared 
using a NEBNext Ultra II RNA Library Prep Kit 
(New England BioLabs). For cell culture isolates, 
RNA was extracted using Trizol reagent, followed 
by sequencing library preparation as described 
above. The library fragment sizes were measured 
using agarose gel electrophoresis and the concentra-
tions using Qubit dsDNA BR Assay Kit (Life 
Technologies, Carlsbad, California, US) and 
NEBNext Library Quant Kit for Illumina (New 
England BioLabs). Sequencing was conducted using 
MiSeq Reagent Kit V2 with 150 bp reads.
Raw sequence reads were trimmed and low- 
quality, quality score <30, and short, <50 nt, 
sequences were removed using Trimmomatic [22]. 
Thereafter, de novo assembly was conducted using 
MegaHit [23]. Contigs were annotated using Blastn 
followed by re-assembly against the de-novo 
assembled CHIKV consensus sequences using BWA- 
MEM algorithm [24] implemented in SAMTools ver-
sion 1.8 [25].
For phylogenetic analysis, all complete CHIKV 
coding sequences were downloaded from the 
GenBank (National Center for Biotechnology 
Information, NCBI). Identical sequences were 
removed using CD-HIT [26] followed by alignment 
using ClustalW algorithm [27] implemented in 
MEGA7 [28]. The phylogenetic tree (Figure 2(a-c)) 
was constructed using the Bayesian Markov chain 
Monte Carlo (MCMC) method, implemented in Mr 
Bayes version 3.2 [29] using a GTR-G-I model of 
substitution with 2 independent runs and 4 chains 
per run. The analysis was run for 5 million states and 
sampled every 5000 steps.
Results
CHIKV nsP2-RT-qPCR
The negative serum panel (n = 15) and controls 
representing other viruses (DENVs, ZIKV, YFVs, 
WNV, ONNV and SINV) all tested as negative by 
CHIKV nsP2-RT-qPCR, showing 100% specificity. 
In order to evaluate the analytical sensitivity of the 
assay, external EQA (EVD-Labnet) samples and 
CHIKV RNA dilutions were tested (Table 3). The 
CHIKV nsP2-RT-qPCR correctly identified 
all CHIKV positive EQA samples (n = 12; 100%), 
as well as the different ten-fold dilutions (10−5-10−8) 
of RNA extracted from cell culture supernatants of 
CHIKV strains Caribbean and Ross (100%). The 
median Ct values (five parallel reactions; standard 
deviation, SD; coefficient variation, CV%) for 
CHIKV Caribbean and Ross dilutions are presented 
in Table 3. The limit of detection was not calculated 
as there were no commercial or in-house purified 
and quantified CHIKV isolates or RNA available. 
However, the Ct value of 37 was considered the cut- 
off for positivity based on the parallel tests (Table 
3). If the Ct value was over 37, the test was repeated 
and positivity was confirmed with other methods.
Clinical samples
Demographic data and laboratory findings are pre-
sented in Table 1. The most frequent source of infec-
tion for Finnish patients was Asia, accounting for 
~60% percent of cases, and particularly Thailand 
(Table 1). This most likely simply reflects the amount 
of Finnish travelers to Asia compared to other 
CHIKV endemic areas. The median age of the 
patients was 35 years (range: 9–70 years) and 16 of 
the patients were female and 18 were male.
Twelve of the acute CHIKV disease patients (n = 34, 
Table 1, Figure 1), were positive using the CHIKV 
Figure 1. Annual variation of serodiagnosed acute CHIKV 
infections in Finland, years 2009–2019.
Table 2. Primers and probes used in CHIKV RT-qPCR assay.
Primer/ 
probe
Sequence (direction 5´→ 3´); gene area: nsP2 protein 
(product size 101 bp), location in CHIKV genome 
(GenBank ID: MH670649.1; NCBI), match (%)
CHIKV-F GAG CAT ACG GTT ACG CAG ATA Ga; 3859–3880, 100%
CHIKV-R1 TAC TGG TGA TAC ATG GTG GTT TCa; 3960–3938, 100%
CHIKV-R2 TGC TGG TGA CAC ATG GTG GTT TCa; 3960–3938, 87%
CHIKV- 
Probe1
FAM-AAT CTG CGT ACT GGG ACG T-MGBNFQb; 
3896–3914, 100%
CHIKV- 
Probe2
FAM-CTG CGT ATT GGG ACG CA -MGBNFQb; 3899–3915, 
78%
CHIKV, chikungunya virus; bp, base pair; F, forward; R, reverse; nsP2, 
nonstructural protein 2; ID, identification code; NCBI, National Center 
for Biotechnology Information, U.S. National Library of Medicine. 
aAdapted from 19 
bDesigned in this study. 
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nsP2-RT-qPCR. From these CHIKV nsP2-RT-qPCR 
positive cases, five (42%) were successfully downstream 
processed using Sanger sequencing and/or NGS. 
Altogether three whole genomes were constructed 
using NGS (Figure 2(a-c)). In this study, the whole- 
genome sequences obtained originated in the 
Caribbean (Jamaica 2014; 33-year-old male) and from 
Thailand (Phuket 2019; 52-year-old female and 51- 
year-old male). In addition, from two samples, 
CHIKV was sequenced using nested-RT-PCR (Sanger 
sequencing).
In the phylogenetic analysis, the strains from 
Thailand clustered within ECSA-lineage and formed 
a sub-cluster together with strains from Bangladesh 
and a Chinese traveler from Bangladesh 2017 Figure 
2(b); [30, 31]. These strains formed a sister clade for 
CHIKV strains sequenced during a CHIKV outbreak 
in Italy in 2017 [32].
The strain from Jamaica clustered within the Asian 
lineage and showed the highest similarity with strains 
sequenced from a Caribbean outbreak during 
2013–2015 Figure 2(c); [33].
The female patient from Thailand had reported 
fever and joint pain as clinical symptoms and the 
male patient had reported fever, rash, mild conjunc-
tivitis, arthralgia, and the inability to walk. The male 
patient also had Legg-Calvé-Perthes disease as a pre- 
existing condition. No clinical symptoms or other 
information was available for the patients who con-
tracted the infection in Jamaica.
We isolated CHIKVs from two CHIKV- 
seronegative patient samples (see serological data 
from Table 1) in Vero cells and confirmed the isola-
tion by CHIKV nsP2-RT-qPCR and NGS from the 
cell culture supernatant. Both of the isolates origi-
nated in Phuket, Thailand, in 2019 (CHIKV-197- 
Finland_ex_Thailand-2019, MN075149; CHIKV-212- 
Finland_ex_Thailand-2019, MN075150). The 
sequences were identical (Figure 2(a)).
None of the other virus isolation attempts out of 
altogether 11 attempts were successful. Virus isola-
tion did not succeed from an EDTA blood sample 
(2019; country visited: Thailand) which was positive 
for CHIKV RNA (Ct 24.5). As there is no validated 
protocol for NGS, an NGS run was not carried out in 
this sample.
Discussion
The CHIKV nsP2-RT-qPCR reaction and protocol 
were optimized for automated sample preparation 
and PCR pipetting robots [MagNA Pure LC instru-
ment (Roche) and QIAgility, Qiagen], and was vali-
dated in diagnostic laboratory settings (HUSLAB). 
The validated CHIKV nsP2-RT-qPCR showed excel-
lent performance with high specificity (100%) and 
good sensitivity and specificity with the EQA samples 
tested. The study was limited by not having 
a calculated limit of detection value due to the fact 
that commercial and quantified CHIKV RNA was not 
available at the time of the study. However, the 
CHIKV RNA was detected in a dilution of 10−8 and 
nsP2-RT-qPCR excellent intra-assay repeatability 
(Table 3). Overall, the data show that this CHIKV 
nsP2-RT-qPCR can be used as a diagnostic assay for 
the detection of acute CHIKV disease in the early 
phase of the infection.
Thirty-four travel-associated CHIKV cases have 
been diagnosed in Finland during 2009–19 (Table 
1). 2019 had the highest number of CHIKV cases 
(Figure 1 and Table 1). In total, 14 (41.2%; 14/34) 
acute cases were diagnosed during that year. We 
collected all serum/blood samples available from all 
of the 34 patients and tested them with the CHIKV 
nsP2-RT-qPCR, and subsequently attempted isola-
tion and Sanger/NGS sequencing from CHIKV nsP2- 
RT-qPCR-positive samples. Twelve CHIKV nsP2-RT 
-qPCR positive samples were detected, and out of 
these 12, two virus isolations succeeded and three 
Figure 2. A phylogenetic tree of complete CHIKV coding 
sequences detected during 2009–2019. (a) All complete 
CHIKV coding sequences acquired from GenBank. 2(b) 
CHIKV strains from Thailand clustered within ECSA-lineage 
(c) CHIKV strain from Jamaica clustered within the Asian 
lineage.
A phylogenetic tree was constructed using the Bayesian Markov 
chain Monte Carlo (MCMC) method, implemented in Mr Bayes ver-
sion 3.2 using a GTR-G-I model of substitution with 2 independent 
runs and 4 chains per run. 
Table 3. Cycle threshold values of two different CHIKV dilu-
tion series using the nsP2 CHIKV RT-qPCR.
Virus
Dilutions 
tested, 10- 
fold
No of posit (x/5 
parallel tests)
Median 
Ct value SD CV%
CHIKV  
Caribbean
10−5 5/5 25.29 0.19 0.5%
10−6 5/5 29.95 0.08 0.3%
10−7 5/5 33.53 0.27 0.8%
10−8 1/5 35.14 ND ND
CHIKV 
Ross
10−5 5/5 26.74 0.12 0.5%
10−6 5/5 28.65 0.22 0.8%
10−7 5/5 31.62 0.20 0.6%
10−8 5/5 36.50 0.35 1.0%
CHIKV, chikungunya virus; posit, positives; ND, not determined; Ct, cycle 
threshold value; SD, standard deviation; CV, coefficient variation. 
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whole-genome sequences were obtained (Figure 
2(a-c)).
In Finnish travelers, most of the CHIKV samples 
positive with CHIKV nsP2-RT- 
qPCR were taken less than one week after the onset 
of symptoms. Overall, the symptoms were typical for 
chikungunya and no fatal CHIKV disease cases have 
been reported in Finland (Table 1).
Nine Finnish patients returning from Thailand 
with severe symptoms have been described previously 
[34]. In these cases, at 10–11 days after the onset of 
symptoms, a low level of CHIKV RNAemia was still 
detected in three individuals using CHIKV nsP2-Rt- 
qPCR.
In 2019, all the CHIKV strains detected from 
Finnish travelers originated in Thailand and clustered 
within ECSA-lineage, subclustering with strains iden-
tified in 2017 in Bangladesh [30,31]. In addition, 
these strains formed a sister clade with the ones 
reported by [32] in Italy, 2017.
In 2014–2015, there was a peak of acute CHIKV 
cases (Figure 1) acquired from Asia and the 
Caribbean. During this time large CHIKV outbreaks 
were reported in the Americas as the CHIKV Asian 
lineage was introduced to and spread widely across 
the Caribbean, South and Central America, and the 
USA (Florida) [33]. These epidemics were also 
reflected in Finnish travelers. The detected CHIKV 
strains from years 2014–15 belonged to Asian lineage 
and had the highest similarity with the strains 
reported to cause the outbreak in the Caribbean dur-
ing 2013–15.
When using serological methods in the diagnosis 
of acute CHIKV infection, samples from acute and 
convalescent phase are needed. This can postpone the 
diagnosis of CHIKV infection. The molecular-based 
diagnostics, however, can be used particularly in the 
early phase and the diagnosis can be confirmed ear-
lier than using serological methods. In addition, sam-
ples with CHIKV genome detected can be further 
used for sequencing and surveillance of CHIKV 
strains circulating. This is as important as vector- 
surveillance for monitoring CHIKV spreading to 
new areas or new strains evolving.
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Key results
● CHIKV strains were isolated and whole gen-
omes were sequenced.
● A realtime RT-qPCR (nsP2-RT-qPCR) was set 
up and validated with Finnish sample panels 
with excellent specificity and sensitivity.
● Automated nucleic acid extraction followed by 
automated pipetting system was tested for 
CHIKV diagnostics.
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